Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about $10 billion, the companies said on Monday.
Shares of Crinetics more than doubled in extended trading, while those of Vertex were marginally down.
Sign up here.
The acquisition gives Vertex access to Palsonify, which was approved by the U.S. Food and Drug Administration in September 2025 t… [791 chars]
Source: Reuters | Published: 2026-07-06T20:10:59Z
Credit: Reuters
